nodes	percent_of_prediction	percent_of_DWPC	metapath
Bimatoprost—AKR1C3—Podofilox—Teniposide—lymphatic system cancer	0.06	0.71	CbGdCrCtD
Bimatoprost—Skin hyperpigmentation—Mechlorethamine—lymphatic system cancer	0.0424	0.0463	CcSEcCtD
Bimatoprost—Conjunctival oedema—Carmustine—lymphatic system cancer	0.0377	0.0412	CcSEcCtD
Bimatoprost—Retinal haemorrhage—Carmustine—lymphatic system cancer	0.0321	0.0351	CcSEcCtD
Bimatoprost—AKR1C3—Vinblastine—Vincristine—lymphatic system cancer	0.0246	0.29	CbGdCrCtD
Bimatoprost—Skin hyperpigmentation—Bleomycin—lymphatic system cancer	0.0202	0.022	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Carmustine—lymphatic system cancer	0.0176	0.0192	CcSEcCtD
Bimatoprost—Urine abnormality—Mitoxantrone—lymphatic system cancer	0.0176	0.0192	CcSEcCtD
Bimatoprost—Chronic obstructive pulmonary disease—Methotrexate—lymphatic system cancer	0.017	0.0185	CcSEcCtD
Bimatoprost—Urine analysis abnormal—Mitoxantrone—lymphatic system cancer	0.0165	0.0181	CcSEcCtD
Bimatoprost—Burning sensation—Carmustine—lymphatic system cancer	0.0151	0.0165	CcSEcCtD
Bimatoprost—Depression—Mechlorethamine—lymphatic system cancer	0.0141	0.0154	CcSEcCtD
Bimatoprost—Scotoma—Carmustine—lymphatic system cancer	0.0138	0.0151	CcSEcCtD
Bimatoprost—Visual disturbance—Fludarabine—lymphatic system cancer	0.0125	0.0137	CcSEcCtD
Bimatoprost—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0125	0.0136	CcSEcCtD
Bimatoprost—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.0117	0.0128	CcSEcCtD
Bimatoprost—Cystitis—Bleomycin—lymphatic system cancer	0.0116	0.0126	CcSEcCtD
Bimatoprost—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.011	0.012	CcSEcCtD
Bimatoprost—Bladder pain—Bleomycin—lymphatic system cancer	0.0108	0.0118	CcSEcCtD
Bimatoprost—Vertigo—Mechlorethamine—lymphatic system cancer	0.00991	0.0108	CcSEcCtD
Bimatoprost—Bronchitis—Fludarabine—lymphatic system cancer	0.00986	0.0108	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00953	0.0104	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00933	0.0102	CcSEcCtD
Bimatoprost—Arthritis—Bleomycin—lymphatic system cancer	0.00895	0.00978	CcSEcCtD
Bimatoprost—Infection—Mechlorethamine—lymphatic system cancer	0.00894	0.00977	CcSEcCtD
Bimatoprost—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00874	0.00955	CcSEcCtD
Bimatoprost—Sinusitis—Fludarabine—lymphatic system cancer	0.00858	0.00937	CcSEcCtD
Bimatoprost—Eye pain—Carmustine—lymphatic system cancer	0.00841	0.00919	CcSEcCtD
Bimatoprost—Pharyngitis—Fludarabine—lymphatic system cancer	0.00815	0.0089	CcSEcCtD
Bimatoprost—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.00815	0.0089	CcSEcCtD
Bimatoprost—Visual impairment—Fludarabine—lymphatic system cancer	0.00791	0.00864	CcSEcCtD
Bimatoprost—Diplopia—Carmustine—lymphatic system cancer	0.0076	0.0083	CcSEcCtD
Bimatoprost—Hypertension—Teniposide—lymphatic system cancer	0.00702	0.00767	CcSEcCtD
Bimatoprost—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00701	0.00766	CcSEcCtD
Bimatoprost—Burning sensation—Methotrexate—lymphatic system cancer	0.00698	0.00762	CcSEcCtD
Bimatoprost—Chest pain—Teniposide—lymphatic system cancer	0.00692	0.00756	CcSEcCtD
Bimatoprost—Infection—Teniposide—lymphatic system cancer	0.00659	0.0072	CcSEcCtD
Bimatoprost—Pruritus—Mechlorethamine—lymphatic system cancer	0.00637	0.00696	CcSEcCtD
Bimatoprost—Cough—Fludarabine—lymphatic system cancer	0.00624	0.00681	CcSEcCtD
Bimatoprost—Dyspnoea—Teniposide—lymphatic system cancer	0.00592	0.00646	CcSEcCtD
Bimatoprost—Depression—Carmustine—lymphatic system cancer	0.00584	0.00638	CcSEcCtD
Bimatoprost—Infection—Fludarabine—lymphatic system cancer	0.00579	0.00633	CcSEcCtD
Bimatoprost—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00572	0.00625	CcSEcCtD
Bimatoprost—Rash—Mechlorethamine—lymphatic system cancer	0.00568	0.0062	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00567	0.0062	CcSEcCtD
Bimatoprost—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00567	0.00619	CcSEcCtD
Bimatoprost—Depression—Vincristine—lymphatic system cancer	0.00557	0.00609	CcSEcCtD
Bimatoprost—Skin discolouration—Methotrexate—lymphatic system cancer	0.00537	0.00586	CcSEcCtD
Bimatoprost—Nausea—Mechlorethamine—lymphatic system cancer	0.00535	0.00584	CcSEcCtD
Bimatoprost—Erythema—Bleomycin—lymphatic system cancer	0.00524	0.00572	CcSEcCtD
Bimatoprost—Dyspnoea—Fludarabine—lymphatic system cancer	0.0052	0.00568	CcSEcCtD
Bimatoprost—Oedema peripheral—Carmustine—lymphatic system cancer	0.00518	0.00565	CcSEcCtD
Bimatoprost—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00516	0.00564	CcSEcCtD
Bimatoprost—Dyspepsia—Fludarabine—lymphatic system cancer	0.00513	0.00561	CcSEcCtD
Bimatoprost—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00511	0.00558	CcSEcCtD
Bimatoprost—Visual impairment—Carmustine—lymphatic system cancer	0.00506	0.00553	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00504	0.0055	CcSEcCtD
Bimatoprost—Inflammation—Methotrexate—lymphatic system cancer	0.005	0.00546	CcSEcCtD
Bimatoprost—Pain—Fludarabine—lymphatic system cancer	0.00499	0.00545	CcSEcCtD
Bimatoprost—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00493	0.00538	CcSEcCtD
Bimatoprost—Eye disorder—Carmustine—lymphatic system cancer	0.00491	0.00536	CcSEcCtD
Bimatoprost—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0049	0.00535	CcSEcCtD
Bimatoprost—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00485	0.0053	CcSEcCtD
Bimatoprost—Asthenia—Teniposide—lymphatic system cancer	0.00476	0.0052	CcSEcCtD
Bimatoprost—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00473	0.00517	CcSEcCtD
Bimatoprost—Pruritus—Teniposide—lymphatic system cancer	0.0047	0.00513	CcSEcCtD
Bimatoprost—Cystitis—Methotrexate—lymphatic system cancer	0.00468	0.00511	CcSEcCtD
Bimatoprost—Erythema—Carmustine—lymphatic system cancer	0.00457	0.005	CcSEcCtD
Bimatoprost—Cough—Bleomycin—lymphatic system cancer	0.00457	0.005	CcSEcCtD
Bimatoprost—Angiopathy—Vincristine—lymphatic system cancer	0.00455	0.00497	CcSEcCtD
Bimatoprost—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00452	0.00494	CcSEcCtD
Bimatoprost—Chest pain—Bleomycin—lymphatic system cancer	0.00446	0.00487	CcSEcCtD
Bimatoprost—Bladder pain—Methotrexate—lymphatic system cancer	0.00438	0.00479	CcSEcCtD
Bimatoprost—Vision blurred—Carmustine—lymphatic system cancer	0.00431	0.00471	CcSEcCtD
Bimatoprost—Erythema—Mitoxantrone—lymphatic system cancer	0.00425	0.00465	CcSEcCtD
Bimatoprost—Infection—Bleomycin—lymphatic system cancer	0.00425	0.00464	CcSEcCtD
Bimatoprost—Asthenia—Fludarabine—lymphatic system cancer	0.00418	0.00457	CcSEcCtD
Bimatoprost—Rash—Teniposide—lymphatic system cancer	0.00418	0.00457	CcSEcCtD
Bimatoprost—Dermatitis—Teniposide—lymphatic system cancer	0.00418	0.00457	CcSEcCtD
Bimatoprost—Headache—Teniposide—lymphatic system cancer	0.00416	0.00454	CcSEcCtD
Bimatoprost—Pruritus—Fludarabine—lymphatic system cancer	0.00413	0.00451	CcSEcCtD
Bimatoprost—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00401	0.00438	CcSEcCtD
Bimatoprost—Hypertension—Carmustine—lymphatic system cancer	0.00395	0.00431	CcSEcCtD
Bimatoprost—Nausea—Teniposide—lymphatic system cancer	0.00394	0.00431	CcSEcCtD
Bimatoprost—Vertigo—Vincristine—lymphatic system cancer	0.00392	0.00429	CcSEcCtD
Bimatoprost—Chest pain—Carmustine—lymphatic system cancer	0.00389	0.00425	CcSEcCtD
Bimatoprost—Anxiety—Carmustine—lymphatic system cancer	0.00388	0.00424	CcSEcCtD
Bimatoprost—Dyspnoea—Bleomycin—lymphatic system cancer	0.00381	0.00417	CcSEcCtD
Bimatoprost—Hypertension—Vincristine—lymphatic system cancer	0.00377	0.00412	CcSEcCtD
Bimatoprost—Visual disturbance—Methotrexate—lymphatic system cancer	0.00371	0.00406	CcSEcCtD
Bimatoprost—Cough—Mitoxantrone—lymphatic system cancer	0.00371	0.00405	CcSEcCtD
Bimatoprost—Infection—Carmustine—lymphatic system cancer	0.00371	0.00405	CcSEcCtD
Bimatoprost—Rash—Fludarabine—lymphatic system cancer	0.00368	0.00402	CcSEcCtD
Bimatoprost—Dermatitis—Fludarabine—lymphatic system cancer	0.00367	0.00401	CcSEcCtD
Bimatoprost—Hypertension—Mitoxantrone—lymphatic system cancer	0.00367	0.00401	CcSEcCtD
Bimatoprost—Pain—Bleomycin—lymphatic system cancer	0.00366	0.004	CcSEcCtD
Bimatoprost—Headache—Fludarabine—lymphatic system cancer	0.00365	0.00399	CcSEcCtD
Bimatoprost—Chest pain—Mitoxantrone—lymphatic system cancer	0.00362	0.00395	CcSEcCtD
Bimatoprost—Anxiety—Mitoxantrone—lymphatic system cancer	0.00361	0.00394	CcSEcCtD
Bimatoprost—Infection—Vincristine—lymphatic system cancer	0.00354	0.00387	CcSEcCtD
Bimatoprost—Nervous system disorder—Vincristine—lymphatic system cancer	0.00349	0.00382	CcSEcCtD
Bimatoprost—Nausea—Fludarabine—lymphatic system cancer	0.00346	0.00378	CcSEcCtD
Bimatoprost—Infection—Mitoxantrone—lymphatic system cancer	0.00345	0.00377	CcSEcCtD
Bimatoprost—Insomnia—Carmustine—lymphatic system cancer	0.00338	0.00369	CcSEcCtD
Bimatoprost—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00337	0.00368	CcSEcCtD
Bimatoprost—Dyspnoea—Carmustine—lymphatic system cancer	0.00333	0.00364	CcSEcCtD
Bimatoprost—Somnolence—Carmustine—lymphatic system cancer	0.00332	0.00363	CcSEcCtD
Bimatoprost—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00325	0.00355	CcSEcCtD
Bimatoprost—Insomnia—Vincristine—lymphatic system cancer	0.00322	0.00352	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00322	0.00352	CcSEcCtD
Bimatoprost—Pain—Carmustine—lymphatic system cancer	0.00319	0.00349	CcSEcCtD
Bimatoprost—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00309	0.00338	CcSEcCtD
Bimatoprost—Somnolence—Mitoxantrone—lymphatic system cancer	0.00309	0.00337	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00308	0.00336	CcSEcCtD
Bimatoprost—Asthenia—Bleomycin—lymphatic system cancer	0.00307	0.00335	CcSEcCtD
Bimatoprost—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00305	0.00334	CcSEcCtD
Bimatoprost—Pain—Vincristine—lymphatic system cancer	0.00305	0.00333	CcSEcCtD
Bimatoprost—Asthma—Methotrexate—lymphatic system cancer	0.00304	0.00332	CcSEcCtD
Bimatoprost—Pruritus—Bleomycin—lymphatic system cancer	0.00303	0.00331	CcSEcCtD
Bimatoprost—Pain—Mitoxantrone—lymphatic system cancer	0.00297	0.00324	CcSEcCtD
Bimatoprost—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00283	0.00309	CcSEcCtD
Bimatoprost—Depression—Methotrexate—lymphatic system cancer	0.0027	0.00295	CcSEcCtD
Bimatoprost—Rash—Bleomycin—lymphatic system cancer	0.0027	0.00295	CcSEcCtD
Bimatoprost—Dermatitis—Bleomycin—lymphatic system cancer	0.00269	0.00294	CcSEcCtD
Bimatoprost—Asthenia—Carmustine—lymphatic system cancer	0.00268	0.00293	CcSEcCtD
Bimatoprost—Asthenia—Vincristine—lymphatic system cancer	0.00256	0.00279	CcSEcCtD
Bimatoprost—Nausea—Bleomycin—lymphatic system cancer	0.00254	0.00278	CcSEcCtD
Bimatoprost—Asthenia—Mitoxantrone—lymphatic system cancer	0.00249	0.00272	CcSEcCtD
Bimatoprost—Dizziness—Carmustine—lymphatic system cancer	0.00247	0.0027	CcSEcCtD
Bimatoprost—Pharyngitis—Methotrexate—lymphatic system cancer	0.00242	0.00264	CcSEcCtD
Bimatoprost—Dizziness—Vincristine—lymphatic system cancer	0.00236	0.00257	CcSEcCtD
Bimatoprost—Rash—Carmustine—lymphatic system cancer	0.00235	0.00257	CcSEcCtD
Bimatoprost—Dermatitis—Carmustine—lymphatic system cancer	0.00235	0.00257	CcSEcCtD
Bimatoprost—Visual impairment—Methotrexate—lymphatic system cancer	0.00235	0.00256	CcSEcCtD
Bimatoprost—Headache—Carmustine—lymphatic system cancer	0.00234	0.00255	CcSEcCtD
Bimatoprost—Eye disorder—Methotrexate—lymphatic system cancer	0.00227	0.00248	CcSEcCtD
Bimatoprost—Rash—Vincristine—lymphatic system cancer	0.00225	0.00245	CcSEcCtD
Bimatoprost—Dermatitis—Vincristine—lymphatic system cancer	0.00224	0.00245	CcSEcCtD
Bimatoprost—Headache—Vincristine—lymphatic system cancer	0.00223	0.00244	CcSEcCtD
Bimatoprost—Nausea—Carmustine—lymphatic system cancer	0.00222	0.00242	CcSEcCtD
Bimatoprost—Angiopathy—Methotrexate—lymphatic system cancer	0.00221	0.00241	CcSEcCtD
Bimatoprost—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00219	0.0024	CcSEcCtD
Bimatoprost—Rash—Mitoxantrone—lymphatic system cancer	0.00219	0.00239	CcSEcCtD
Bimatoprost—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00219	0.00239	CcSEcCtD
Bimatoprost—Headache—Mitoxantrone—lymphatic system cancer	0.00217	0.00238	CcSEcCtD
Bimatoprost—Erythema—Methotrexate—lymphatic system cancer	0.00212	0.00231	CcSEcCtD
Bimatoprost—Nausea—Vincristine—lymphatic system cancer	0.00212	0.00231	CcSEcCtD
Bimatoprost—Nausea—Mitoxantrone—lymphatic system cancer	0.00206	0.00225	CcSEcCtD
Bimatoprost—Vision blurred—Methotrexate—lymphatic system cancer	0.002	0.00218	CcSEcCtD
Bimatoprost—Vertigo—Methotrexate—lymphatic system cancer	0.0019	0.00208	CcSEcCtD
Bimatoprost—Cough—Methotrexate—lymphatic system cancer	0.00185	0.00202	CcSEcCtD
Bimatoprost—Chest pain—Methotrexate—lymphatic system cancer	0.0018	0.00197	CcSEcCtD
Bimatoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00179	0.00196	CcSEcCtD
Bimatoprost—Infection—Methotrexate—lymphatic system cancer	0.00172	0.00188	CcSEcCtD
Bimatoprost—Nervous system disorder—Methotrexate—lymphatic system cancer	0.0017	0.00185	CcSEcCtD
Bimatoprost—Skin disorder—Methotrexate—lymphatic system cancer	0.00168	0.00183	CcSEcCtD
Bimatoprost—Insomnia—Methotrexate—lymphatic system cancer	0.00156	0.00171	CcSEcCtD
Bimatoprost—Dyspnoea—Methotrexate—lymphatic system cancer	0.00154	0.00168	CcSEcCtD
Bimatoprost—Somnolence—Methotrexate—lymphatic system cancer	0.00154	0.00168	CcSEcCtD
Bimatoprost—Dyspepsia—Methotrexate—lymphatic system cancer	0.00152	0.00166	CcSEcCtD
Bimatoprost—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00149	0.00163	CcSEcCtD
Bimatoprost—Pain—Methotrexate—lymphatic system cancer	0.00148	0.00162	CcSEcCtD
Bimatoprost—Asthenia—Methotrexate—lymphatic system cancer	0.00124	0.00136	CcSEcCtD
Bimatoprost—Pruritus—Methotrexate—lymphatic system cancer	0.00122	0.00134	CcSEcCtD
Bimatoprost—Dizziness—Methotrexate—lymphatic system cancer	0.00114	0.00125	CcSEcCtD
Bimatoprost—Rash—Methotrexate—lymphatic system cancer	0.00109	0.00119	CcSEcCtD
Bimatoprost—Dermatitis—Methotrexate—lymphatic system cancer	0.00109	0.00119	CcSEcCtD
Bimatoprost—Headache—Methotrexate—lymphatic system cancer	0.00108	0.00118	CcSEcCtD
Bimatoprost—Nausea—Methotrexate—lymphatic system cancer	0.00103	0.00112	CcSEcCtD
